Pharmaceutical Development of Antibody Drug Conjugates, Live with Q&A
Dr. Sacha is a senior research scientist at Baxter Healthcare located in Bloomington, IN. He is responsible for contract formulation and process development of sterile products with a specialty in freeze-drying. Dr. Sacha has several formulation patents including ones for ADCs that were developed in the laboratory in Bloomington and transferred to full-scale manufacturing at the Baxter site in a Halle, Germany. His interests include formulation development for large molecules, thermal characterization, and freeze-drying operations and equipment.
Antibody drug conjugates (ADCs) are antibodies equipped with a small number of chemotherapeutic molecules with the aid of a linker system. They have grown in importance because the antibody targets specific cells where they drop off their payload of chemotherapeutic molecules. This is a huge advantage to chemotherapy. The traditional approach to chemotherapy is to administer a large quantity of the drug to the patient and this results in significant side effects. ADCs provide a targeted delivery system that reduces the severe side effects of the chemotherapeutic agent. Many ADCs are not sufficiently stable in solution and are instead developed as freeze-dried solids. This presentation discusses ADCs, their linker systems, development of a freeze-dried formulation, and potential challenges.
- This webinar provides examples of ADCs and how they work
- Formulation Development of an ADC
- Considerations for full-scale manufacturing